<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968070</url>
  </required_header>
  <id_info>
    <org_study_id>15181</org_study_id>
    <secondary_id>I7A-MC-EACA</secondary_id>
    <nct_id>NCT01968070</nct_id>
  </id_info>
  <brief_title>A Study of LY3127760 in Healthy Participants</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to evaluate the safety and how well the body handles
      single and multiple doses of increasing strength of study drug, LY3127760. This study
      includes three parts. Part 3 may be initiated at sponsor's discretion, based on data from
      Part 2. Participants will only enroll in 1 of the 3 study parts. This study will last
      approximately 7 to 13 weeks, depending on part. Screening must be completed within 28 days
      prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (Up To Day 42)</time_frame>
    <description>Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve From Zero to Infinity (AUC 0-∞) of Single Dose LY3127760</measure>
    <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of Single Dose LY3127760</measure>
    <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of Maximum Observed Concentration (Tmax) of Single Dose LY3127760</measure>
    <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC-tau (τ)] of Multiple Doses LY3127760</measure>
    <time_frame>Day 28: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 Hours</time_frame>
    <description>AUC-tau (τ) where τ is 24-hours for the 20 mg, 60 mg, and 200 mg cohorts, and 12-hours for the 300 mg cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Multiple Doses LY3127760</measure>
    <time_frame>Post last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Tmax of Multiple Doses LY3127760</measure>
    <time_frame>Post-last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Single)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple oral doses of 400 mg celecoxib administered QD for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3127760</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Single)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Single)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females as determined by medical history and physical
             examination

          -  Male participants agree to use a reliable method of birth control during the study and
             3 months following the last dose of the investigational product

          -  Female participants not of child-bearing potential

          -  Have a body mass index of 18.5 to 32 kilograms per square meter (kg/m^2) inclusive

          -  Are normotensive (defined as supine systolic blood pressure [BP] less than 140
             millimeters of mercury [mm Hg] and diastolic BP less than 90 mm Hg) without use of any
             antihypertensives

        Exclusion Criteria:

          -  Have known allergies to LY3127760, related compounds or any components of the
             formulation, celecoxib or sulfonamides, or history of significant atopy. Participants
             with known aspirin allergy or allergic reactions to nonsteroidal anti-inflammatory
             drugs (NSAIDs) should also be excluded

          -  Have any current or prior history of a significant gastrointestinal illness such as
             peptic ulcer disease, gastrointestinal (GI) bleeding, chronic gastritis, inflammatory
             bowel disease or chronic diarrhea

          -  Have evidence of other chronic liver disease, including but not limited to chronic
             alcoholic disease, nonalcoholic steatohepatitis, recent history (within 3 months of
             screening) of acute viral hepatitis or chronic autoimmune hepatitis

          -  Have used any NSAIDs, celecoxib, aspirin or acetaminophen (at doses greater than 1
             gram per day), anticoagulants or antiplatelet agents within 14 days of admission

        Part 2 and Part 3 only

          -  Have 1 plus pretrial pitting edema or 2 plus ankle or pedal edema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>September 27, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part 1 was a single-ascending dose, 2-cohort, 3-period, alternating-group dose-escalation study (cohorts 1-2) and Part 2 of the study was a multiple-ascending dose, 4-cohort, parallel-group, dose-escalation study (cohorts 3-6). Replacement participants received interventions intended for those participants whom discontinued early.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 Sequence 1</title>
          <description>Participants received either placebo or 20 milligram (mg) or 200mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 20mg LY3127760; Period 2: 200mg LY3127760; Period 3: Placebo;</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 Sequence 2</title>
          <description>Participants received either placebo or 20 milligram (mg) or 900mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 20mg LY3127760; Period 2: Placebo; Period 3: 900mg LY3127760;</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 Sequence 3</title>
          <description>Participants received either placebo or 200 milligram(mg) or 900mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: Placebo; Period 2: 200 mg LY3127760; Period 3: 900 mg LY3127760;</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 Sequence 1</title>
          <description>Participants received either 60mg or 600mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 60 mg LY3127760; Period 2: 600 mg LY3127760; Period 3: 600 mg LY3127760 in fasting state;</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2 Sequence 2</title>
          <description>Participants received either placebo or 60 mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 60 mg LY3127760; Period 2: Placebo; Period 3: Placebo;</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2 Sequence 3</title>
          <description>Participants received either Placebo or 600 mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: Placebo; Period 2: 600 mg LY3127760; Period 3: 600 mg LY3127760 in fasting state;</description>
        </group>
        <group group_id="P7">
          <title>Cohort 3 LY3127760 60mg</title>
          <description>Participants received 60mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 3 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 4 LY3127760 200mg</title>
          <description>Participants received 200mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 4 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="P12">
          <title>Cohort 4 Celcoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="P13">
          <title>Cohort 5 LY3127760 20mg</title>
          <description>Participants received 20mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="P14">
          <title>Cohort 5 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="P15">
          <title>Cohort 5 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="P16">
          <title>Cohort 6 LY3127760 600mg</title>
          <description>Participants received 300mg LY3127760 capsules orally twice daily.</description>
        </group>
        <group group_id="P17">
          <title>Cohort 6 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="P18">
          <title>Cohort 6 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4">1 participant was added to replace the participant who discontinued the period 1.</participants>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4">2 participants were added to replace the 2 participants who discontinued the period 1.</participants>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P8" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P9" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P10" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P11" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P12" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P13" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P14" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P15" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P16" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P17" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
                <participants group_id="P18" count="0">Part 2 (Cohorts 3 to 6) was planned only for one period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 Sequence 1</title>
          <description>Participants received either placebo or 20 milligram (mg) or 200mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 20mg LY3127760; Period 2: 200mg LY3127760; Period 3: Placebo;</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 Sequence 2</title>
          <description>Participants received either placebo or 20 milligram (mg) or 900mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 20mg LY3127760; Period 2: Placebo; Period 3: 900mg LY3127760;</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1 Sequence 3</title>
          <description>Participants received either placebo or 200 milligram(mg) or 900mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: Placebo; Period 2: 200 mg LY3127760; Period 3: 900 mg LY3127760;</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 Sequence 1</title>
          <description>Participants received either 60mg or 600mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 60 mg LY3127760; Period 2: 600 mg LY3127760; Period 3: 600 mg LY3127760 in fasting state;</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2 Sequence 2</title>
          <description>Participants received either placebo or 60 mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: 60 mg LY3127760; Period 2: Placebo; Period 3: Placebo;</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2 Sequence 3</title>
          <description>Participants received either Placebo or 600 mg LY3127760 capsules orally as per the below dosing sequence.
Period 1: Placebo; Period 2: 600 mg LY3127760; Period 3: 600 mg LY3127760 in fasting state;</description>
        </group>
        <group group_id="B7">
          <title>Cohort 3 LY3127760 60mg</title>
          <description>Participants received 60mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 3 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 3 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 4 LY3127760 200mg</title>
          <description>Participants received 200mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="B11">
          <title>Cohort 4 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="B12">
          <title>Cohort 4 Celcoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="B13">
          <title>Cohort 5 LY3127760 20mg</title>
          <description>Participants received 20mg LY3127760 capsules orally once daily.</description>
        </group>
        <group group_id="B14">
          <title>Cohort 5 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="B15">
          <title>Cohort 5 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="B16">
          <title>Cohort 6 LY3127760 300mg</title>
          <description>Participants received 300mg LY3127760 capsules orally twice daily.</description>
        </group>
        <group group_id="B17">
          <title>Cohort 6 Placebo</title>
          <description>Participants received placebo capsules orally once daily.</description>
        </group>
        <group group_id="B18">
          <title>Cohort 6 Celecoxib 400mg</title>
          <description>Participants received 400mg Celecoxib capsules orally once daily.</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="2"/>
            <count group_id="B12" value="2"/>
            <count group_id="B13" value="9"/>
            <count group_id="B14" value="2"/>
            <count group_id="B15" value="2"/>
            <count group_id="B16" value="9"/>
            <count group_id="B17" value="2"/>
            <count group_id="B18" value="2"/>
            <count group_id="B19" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="9"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="9"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="9"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline to Study Completion (Up To Day 42)</time_frame>
        <population>All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Placebo, Single Dose Administered PO</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 600 mg LY3127760</title>
            <description>600 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 600 mg LY3127760 (Fasted)</title>
            <description>600 mg LY3127760 Single Dose Administered PO During Fasted State</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 900 mg LY3127760</title>
            <description>900 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Placebo</title>
            <description>Placebo administered PO, once a day (QD), for 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: 20 mg LY3127760</title>
            <description>20 mg LY3127760 administered PO, QD, for 28 days.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: 60 mg LY3127760</title>
            <description>60 mg LY3127760 administered PO, QD, for 28 days.</description>
          </group>
          <group group_id="O11">
            <title>Part 2: 200 mg LY3127760</title>
            <description>200 mg LY3127760 administered PO, QD, for 28 days.</description>
          </group>
          <group group_id="O12">
            <title>Part 2: 300 mg LY3127760</title>
            <description>300 mg LY3127760 administered PO, twice daily (BID), for 28 days.</description>
          </group>
          <group group_id="O13">
            <title>Part 2: 400 mg Celecoxib</title>
            <description>Celecoxib administered PO, QD, for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.</description>
          <population>All randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve From Zero to Infinity (AUC 0-∞) of Single Dose LY3127760</title>
        <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 600 mg LY3127760</title>
            <description>600 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 600 mg LY3127760 (Fasted)</title>
            <description>600 mg LY3127760 Single Dose Administered PO During a Fasted State</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 900 mg LY3127760</title>
            <description>900 mg LY3127760 Single Dose Administered PO</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve From Zero to Infinity (AUC 0-∞) of Single Dose LY3127760</title>
          <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable AUC data.</population>
          <units>nanograms•hour/milliliter (ng•hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated because multiple concentrations were below the detection limit of the assay</measurement>
                    <measurement group_id="O2" value="3010" spread="42"/>
                    <measurement group_id="O3" value="17200" spread="9"/>
                    <measurement group_id="O4" value="40000" spread="17"/>
                    <measurement group_id="O5" value="47400" spread="20"/>
                    <measurement group_id="O6" value="71900" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Maximum Observed Concentration (Cmax) of Single Dose LY3127760</title>
        <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 600 mg LY3127760</title>
            <description>600 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 600 mg LY3127760 (Fasted)</title>
            <description>600 mg LY3127760 Single Dose Administered PO During a Fasted State</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 900 mg LY3127760</title>
            <description>900 mg LY3127760 Single Dose Administered PO</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Observed Concentration (Cmax) of Single Dose LY3127760</title>
          <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable Cmax data.</population>
          <units>nanograms/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264" spread="41"/>
                    <measurement group_id="O2" value="890" spread="19"/>
                    <measurement group_id="O3" value="3880" spread="33"/>
                    <measurement group_id="O4" value="10300" spread="37"/>
                    <measurement group_id="O5" value="18900" spread="40"/>
                    <measurement group_id="O6" value="21600" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Time of Maximum Observed Concentration (Tmax) of Single Dose LY3127760</title>
        <time_frame>Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable Tmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 600 mg LY3127760</title>
            <description>600 mg LY3127760 Single Dose Administered PO</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 600 mg LY3127760 (Fasted)</title>
            <description>600 mg LY3127760 Single Dose Administered PO During a Fasted State</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 900 mg LY3127760</title>
            <description>900 mg LY3127760 Single Dose Administered PO</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time of Maximum Observed Concentration (Tmax) of Single Dose LY3127760</title>
          <population>All randomized participants who received at least one dose of study drug for the single dose in Part 1 and had evaluable Tmax data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.02"/>
                    <measurement group_id="O3" value="2.00" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.52" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC-tau (τ)] of Multiple Doses LY3127760</title>
        <description>AUC-tau (τ) where τ is 24-hours for the 20 mg, 60 mg, and 200 mg cohorts, and 12-hours for the 300 mg cohort.</description>
        <time_frame>Day 28: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 300 mg LY3127760</title>
            <description>300 mg LY3127760 Administered BID PO, Day 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC-tau (τ)] of Multiple Doses LY3127760</title>
          <description>AUC-tau (τ) where τ is 24-hours for the 20 mg, 60 mg, and 200 mg cohorts, and 12-hours for the 300 mg cohort.</description>
          <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable AUC data.</population>
          <units>ng•hr/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020" spread="20"/>
                    <measurement group_id="O2" value="4350" spread="50"/>
                    <measurement group_id="O3" value="11300" spread="23"/>
                    <measurement group_id="O4" value="19700" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax of Multiple Doses LY3127760</title>
        <time_frame>Post last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 300 mg LY3127760</title>
            <description>300 mg LY3127760 Administered BID PO, Day 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of Multiple Doses LY3127760</title>
          <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable Cmax data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301" spread="19"/>
                    <measurement group_id="O2" value="1210" spread="53"/>
                    <measurement group_id="O3" value="3650" spread="27"/>
                    <measurement group_id="O4" value="6170" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Tmax of Multiple Doses LY3127760</title>
        <time_frame>Post-last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable Tmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 20 mg LY3127760</title>
            <description>20 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 60 mg LY3127760</title>
            <description>60 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 200 mg LY3127760</title>
            <description>200 mg LY3127760 Administered QD PO, Day 1-28</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 300 mg LY3127760</title>
            <description>300 mg LY3127760 Administered BID PO, Day 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Tmax of Multiple Doses LY3127760</title>
          <population>All randomized participants who received at least one dose of study drug for multiple dosing in Part 2 and had evaluable Tmax data.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.65" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.02"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Two participants were randomized into a Part 1 scheme where they received placebo 2 out of the 3 dosing periods. Those participants are represented only once in the placebo arm in adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part 1)</title>
          <description>Placebo, Single Dose Administered PO</description>
        </group>
        <group group_id="E2">
          <title>20 mg LY3127760 (Part 1)</title>
          <description>20 mg LY3127760 Single Dose Administered PO</description>
        </group>
        <group group_id="E3">
          <title>60 mg LY3127760 (Part 1)</title>
          <description>60 mg LY3127760 Single Dose Administered PO</description>
        </group>
        <group group_id="E4">
          <title>200 mg LY3127760 (Part 1)</title>
          <description>200 mg LY3127760 Single Dose Administered PO</description>
        </group>
        <group group_id="E5">
          <title>600 mg LY3127760 (Part 1)</title>
          <description>600 mg LY3127760 Single Dose Administered PO</description>
        </group>
        <group group_id="E6">
          <title>600 mg LY3127760 (Fasted) (Part 1)</title>
          <description>600 mg LY3127760 Single Dose Administered PO During Fasted State</description>
        </group>
        <group group_id="E7">
          <title>900 mg LY3127760 (Part 1)</title>
          <description>900 mg LY3127760 Single Dose Administered PO</description>
        </group>
        <group group_id="E8">
          <title>Placebo (Part 2)</title>
          <description>Placebo, Administered QD PO, Day 1-28</description>
        </group>
        <group group_id="E9">
          <title>20 mg LY3127760 (Part 2)</title>
          <description>20 mg LY3127760 Administered QD PO, Day 1-28</description>
        </group>
        <group group_id="E10">
          <title>60 mg LY3127760 (Part 2)</title>
          <description>60 mg LY3127760 Administered QD PO, Day 1-28</description>
        </group>
        <group group_id="E11">
          <title>200 mg LY3127760 (Part 2)</title>
          <description>200 mg LY3127760 Administered QD PO, Day 1-28</description>
        </group>
        <group group_id="E12">
          <title>300 mg LY3127760 (Part 2)</title>
          <description>300 mg LY3127760 Administered BID PO, Day 1-28</description>
        </group>
        <group group_id="E13">
          <title>400 mg Celecoxib (Part 2)</title>
          <description>400 mg celecoxib Administered QD PO, Day 1-28</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

